HOME >> BIOLOGY >> NEWS
Emory scientists find new prostate cancer suppressor gene

ATLANTA--A gene named ATBF1 may contribute to the development of prostate cancer through acquired mutations and/or loss of expression, according to research at Emory University School of Medicine and its Winship Cancer Institute. The findings were published in the online edition of Nature Genetics on March 6. The Emory research team was led by Jin-Tang Dong, PhD, associate professor in the Winship Cancer Institute. Lead author was postdoctoral fellow Xiaodong Sun, PhD.

Although previous research has suggested that a section of chromosome 16 harbors a tumor suppressor gene in several types of human cancers, the particular gene responsible has not previously been identified. By studying the genes within the section of chromosome 16, the Emory scientists found that ATBF1 was a strong candidate for an important tumor suppressor gene because its function is frequently lost in prostate cancer through gene mutations and/or loss of expression. In addition, ATBF1 was found to inhibit cell growth in culture dishes. A tumor suppressor gene is a gene whose loss of function contributes to the development of cancer.

ATBF1 is a transcription factor (regulator of gene expression) that functions to regulate the expression of other genes. If its function is impaired by mutations or loss of expression, a cell could lose the control of cancer genes. The Myb oncogene, for example, is normally inhibited by ATBF1, but it can be activated if ATBF1 is lost.

"Sporadic cancers often are the result of multiple genetic alterations that accumulate over time," said Dr. Dong, "but only a small number of genes have been shown to undergo these frequent mutations. Because ATBF1 inhibits cell proliferation, frequent acquired mutations that inhibit the gene, such as the ones we found, could lead to a lack of growth control in prostate cancer. Because gene deletion in chromosome 16 is common in many types of cancer, including lung, head and neck, nasopharynx, stomach, breast, and
'"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University Health Sciences Center
22-Mar-2005


Page: 1 2

Related biology news :

1. New genetic test developed at Emory advances detection and diagnosis of muscular dystrophy
2. Emory scientists develop new map of genetic variation in human genome
3. Hormones may affect how brain listens, Emory study finds
4. Emory scientists discover unique binding method for essential cellular protein ubiquitin
5. Blood conservation strategies take center stage at Emory University Hospital forum
6. NIH awards Georgia Tech/Emory $11.5 M for nano cardiology research
7. Emory scientist finds different paths lead to similar cognitive abilities
8. Emory study finds monarch health tied to migration
9. Emory researchers find more evidence for childrens growth spurts, pain
10. Emory biochemist writes lead essay describing Nobel Prize research on ubiquitin protein
11. Emory study details dolphin brain evolution for the first time

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... March 23, 2017 The report "Gesture Recognition and Touchless ... and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is ... of 29.63% between 2017 and 2022. Continue Reading ... ... ...
(Date:3/20/2017)... , March 20, 2017 At this year,s ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand ... is this year,s CeBIT partner country. At the largest German biometrics ... in use: fingerprint, face and iris recognition as well as DERMALOGĀ“s multi-biometrics ... ...
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, ... Simple," and 23andMe , the leading personal genetics ... choices.  Zipongo can now provide customers with personalized nutrition ... goals and biometrics, but also genetic markers impacting how ... Zipongo,s personalized food decision support platform uses biometrics ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... 23, 2017 In today,s pre-market ... in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), ... MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." ... report at: ...
(Date:3/22/2017)... ... March 22, 2017 , ... Researchers ... from small lab samples to full-size tissues, bones, even whole organs to implant ... system that delivers blood deep into the developing tissue. , Current bioengineering ...
(Date:3/22/2017)... -- Good Start Genetics, a leading family genomics company, ... covered lives mark through its most recent payor addition, ... . With newly signed contracts nationally and others in ... acceptance based on the quality of its science, the ... industry-leading customer care and support and its published cost-effectiveness ...
(Date:3/22/2017)... The global chronic kidney disease ... by Transparency Market Research (TMR). The top four players, ... Inc., accounted for a share of only 41.4% in ... market are focusing aggressively on mergers, acquisitions, and strategic ... to lead to market consolidation in the next few ...
Breaking Biology Technology:
Cached News: